Transgene SA (EPA:TNG)
0.6660
+0.0060 (0.91%)
Apr 1, 2025, 12:30 PM CET
Transgene Employees
Transgene had 141 employees as of December 31, 2023. The number of employees decreased by 5 or -3.42% compared to the previous year.
Employees
141
Change (1Y)
-5
Growth (1Y)
-3.42%
Revenue / Employee
€43,514
Profits / Employee
€232,678
Market Cap
87.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sanofi | 82,878 |
EssilorLuxottica Société anonyme | 153,498 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 13,982 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
Virbac | 5,459 |
emeis Société anonyme | 77,954 |
Transgene News
- 6 months ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 1 year ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 2 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 2 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 2 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 2 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 2 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire